Radius Health Inc (RDUS) Releases Earnings Results, Misses Expectations By $-0.07 EPS

Radius Health Inc (RDUS) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-1.01 earnings per share for the quarter, missing the analyst consensus estimate by $-0.07. Analysts had a consensus of $-0.94. During the same quarter in the previous year, the company posted $-0.61 EPS.

Many Wall Street Analysts have commented on Radius Health Inc. H.C. Wainwright Initiated Radius Health Inc on May 23, 2016 to “Buy”, Price Target of the shares are set at $55.

Radius Health Inc opened for trading at $46.9 and hit $49.55 on the upside on Tusday, eventually ending the session at $48.98, with a gain of 4.19% or 1.97 points. The heightened volatility saw the trading volume jump to 10,05,597 shares. Company has a market cap of $2,108 M.

In a different news, on Jan 27, 2016, Lorraine A. Fitzpatrick (Chief Medical Officer) purchased 200 shares at $49.28 per share price. According to the SEC, on Nov 25, 2015, Robert Ward (President & CEO) sold 25,000 shares at $62.76 per share price. On Nov 13, 2015, Gary Hattersley (Chief Scientific Officer) sold 5,683 shares at $75.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Radius Health Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (BA058) a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch which the Company refers to as abaloparatide-TD. The Company’s clinical product portfolio also includes the investigational drug RAD1901 a selective estrogen receptor down regulator/degrader (SERD) and RAD140 a nonsteroidal selective androgen receptor modulator (SARM) for the treatment of breast cancer.

Radius Health Inc

Leave a Reply

Radius Health Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Radius Health Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.